Observational studyThe Journal of clinical endocrinology and metabolism2020
Vasomotor Symptoms and Accelerated Epigenetic Aging in the Women's Health Initiative (WHI).
Observational study in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06975111 (Focusing on the Menopausal Transition to Improve Mid-Life Women's Health), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Risk factors, management and consequences of severe menopausal vasomotor symptoms.Nature reviews. Endocrinology · 2026Review
- One size does not fit all: how type of menopause and hormone therapy matters for brain health.The British journal of psychiatry : the journal of mental science · 2025Review
- An Evaluation of DNA Methylation Levels and Sleep in Relation to Hot Flashes: A Cross-Sectional Study.Journal of clinical medicine · 2024Article
- Vasomotor symptoms and cardiovascular health: findings from the SWAN and the MsHeart/MsBrain studies.Climacteric : the journal of the International Menopause Society · 2024Review
- DNA methylation as a window into female reproductive aging.Epigenomics · 2024Review
- Vasomotor symptoms and their links to cardiovascular disease risk.Current opinion in endocrine and metabolic research · 2023Article
- The epigenetic aging, obesity, and lifestyle.Frontiers in cell and developmental biology · 2022Review
- Menopausal symptoms and risk of heart failure: a retrospective analysis from Taiwan National Health Insurance Database.ESC heart failure · 2021Article
- Article
- Epigenetic clocks may come out of rhythm-implications for the estimation of chronological age in forensic casework.International journal of legal medicine · 2020Review
- Hypertensive disorders of pregnancy and menopausal symptoms: a cross-sectional study from the data registry on experiences of aging, menopause, and sexuality.Menopause (New York, N.Y.) · 2020Article
- Individual species and cumulative mixture relationships of 24-hour urine metal concentrations with DNA methylation age variables in older men.Environmental research · 2020Article
- Are there differences in symptoms experienced by midlife climacteric women with and without metabolic syndrome? A scoping review.Women's health (London, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
Abstract
purposeThe hallmark menopausal symptom, vasomotor symptoms (VMS), has been linked to adverse health indicators. However, the relationship between VMS and biological aging has not been tested. We examined associations between menopausal VMS and biological aging as assessed by 2 DNA methylation-based epigenetic aging indicators previously linked to poor health outcomes.
methodsParticipants were members of the Women's Health Initiative Observational Study integrative genomics substudy (N = 1206) who had both ovaries and were not taking hormone therapy. Relationships between VMS at enrollment (presence, severity) or VMS timing groups (no VMS: not at menopause onset nor at study enrollment; early VMS: at menopause onset but not at enrollment; persistent VMS: at menopause onset and study enrollment; and late VMS: at enrollment but not at menopause onset) and epigenetic clock indicators predictive of physical aging and early death (DNAm PhenoAge, DNAm GrimAge) were tested in linear regression models adjusting for age, race/ethnicity, hysterectomy, education, body mass index, smoking, and, in additional models, sleep disturbance.
resultsWomen were on average 65 years of age at enrollment. Severe hot flashes at enrollment were associated with higher DNAm PhenoAge [relative to no hot flashes: B (SE) = 2.79 (1.27), P = 0.028, multivariable]. Further, late-occurring VMS were associated with both higher DNAm PhenoAge [B (SE) = 2.15 (0.84), P = 0.011] and DNAm GrimAge [B (SE) = 1.09 (0.42), P = 0.010, multivariable] relative to no VMS. MAIN
conclusionsAmong postmenopausal women, severe or late-occurring VMS were associated with accelerated epigenetic age, controlling for chronological age. Postmenopausal women with severe or late-occurring VMS may have greater underlying epigenetic aging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.